Target intelligence / Profile preview

Alpha-like protein family N-terminal domain (Alp NTD)

Target
Alp NTD
Molecular classification
Bacterial surface protein, Adhesin, Virulence factor
01

Overview

The N-terminal domains of the alpha-like protein (Alp) family are critical surface-exposed virulence factors of Group B Streptococcus (GBS; Streptococcus agalactiae) (PubMed: 24511471). This protein family includes members such as Alpha C protein (ACP), Rib, Alp1, Alp2, Alp3, and Alp4, which share a common structural architecture consisting of a conserved N-terminal domain (NTD) followed by a variable number of tandem repeats (PubMed: 15103027). These NTDs are primarily involved in bacterial adhesion to host epithelial cells and the invasion of vaginal and neonatal barriers, which are essential steps in the progression of GBS infection (PubMed: 27161805). Because the NTDs are highly immunogenic and their structural folds are relatively conserved across different GBS clinical isolates, they serve as primary targets for recombinant subunit vaccine development (MinervaX, 2024). Therapeutic strategies, such as the GBS-NN and GBS-NN2 vaccines, utilize these recombinant domains to elicit high titers of opsonophagocytic antibodies in pregnant women. These antibodies are then transplacentally transferred to the fetus, providing passive immunity to protect neonates from life-threatening conditions like sepsis and meningitis (PubMed: 33159130).

Other names
Alp family N-terminal domainsGroup B Streptococcus surface protein N-terminal domainsGBS Alp NTDsAlpha-like protein N-terminal regions
02

Mechanism of action

Vaccine-mediated induction of protective opsonophagocytic antibodies (OPA) that neutralize bacterial adhesion to host cells and promote immune-mediated clearance by phagocytes (PubMed: 33159130).

03

Biological functions

Bacterial adhesionHost cell invasionImmune evasion
04

Disease associations

Group B Streptococcal infectionNeonatal sepsisMeningitisPneumonia
05

Safety considerations

Strain-specific coverage gaps due to protein variabilityPotential for immune escape through domain variationMaternal-fetal safety considerations inherent to prenatal vaccination
06

Interacting drugs

GBS-NN vaccine

1 more in the full profile.

07

Biomarkers

Anti-Alp NTD IgG antibody concentrationOpsonophagocytic killing assay (OPKA) titers

Beyond the preview

Go deeper on Alpha-like protein family N-terminal domain (Alp NTD).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-like protein family N-terminal domain (Alp NTD).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call